NextCure (NASDAQ:NXTC) Major Shareholder Adar1 Capital Management, Llc Buys 36,303 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 36,303 shares of the company’s stock in a transaction dated Friday, July 31st. The stock was bought at an average cost of $4.94 per share, with a total value of $179,336.82. Following the completion of the transaction, the insider owned 722,419 shares in the company, valued at approximately $3,568,749.86. This trade represents a 5.29% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, July 30th, Adar1 Capital Management, Llc bought 292,850 shares of NextCure stock. The shares were bought at an average cost of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The shares were bought at an average price of $5.00 per share, for a total transaction of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc purchased 6,400 shares of NextCure stock. The shares were bought at an average price of $4.95 per share, for a total transaction of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc purchased 7,798 shares of NextCure stock. The stock was bought at an average cost of $5.00 per share, with a total value of $38,990.00.

NextCure Price Performance

Shares of NXTC opened at $4.40 on Tuesday. NextCure, Inc. has a one year low of $1.55 and a one year high of $15.74. The company has a 50-day simple moving average of $3.42 and a two-hundred day simple moving average of $8.59. The firm has a market capitalization of $15.88 million, a PE ratio of -0.26 and a beta of 1.26.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23. Analysts expect that NextCure, Inc. will post -7.89 EPS for the current fiscal year.

Institutional Trading of NextCure

Hedge funds have recently made changes to their positions in the stock. Cable Car Capital LP increased its position in NextCure by 13.1% during the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after buying an additional 88,040 shares in the last quarter. Affinity Asset Advisors LLC raised its stake in NextCure by 28.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after buying an additional 55,412 shares during the last quarter. Ikarian Capital LLC bought a new stake in NextCure in the fourth quarter worth $3,382,000. Squadron Capital Management LLC purchased a new stake in shares of NextCure in the fourth quarter worth $3,363,000. Finally, Exome Asset Management LLC purchased a new stake in shares of NextCure in the fourth quarter worth $2,341,000. 42.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NXTC. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 7th. Wall Street Zen lowered NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of NextCure in a research report on Wednesday, July 15th. Finally, Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.